SARS-CoV-2 B.1.351 and B.1.167.2 viruses used in this study were
obtained through the European Virus Archive Global (EVA-GLOBAL)
project that has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 653316. SARS-CoV-2 B.1 (MAD6 isolate) was kindly provided by José M. Honrubia and Luis Enjuanes (CNB-CSIC, Madrid,
Spain). The authors thank Centro de Investigación en Sanidad Animal (CISA)-Instituto Nacional de Investigaciones Agrarias (INIA-CSIC)
(Valdeolmos, Madrid, Spain) for the BSL-3 facilities. Research in LAV laboratory was funded by the BBVA Foundation (Ayudas Fundación BBVA a Equipos de Investigación Científica SARS-CoV-2 y COVID19); the MCIN/AEI/10.13039/501100011033 (PID2020-117323RB-I00 and
PDC2021-121711-I00), partially supported by the European Regional
Development Fund (ERDF); the Carlos III Health Institute (ISCIII)
(DTS20/00089), partially supported by the ERDF, the Spanish Association Against Cancer (AECC 19084); the CRIS Cancer Foundation (FCRISIFI-2018 and FCRIS-2021-0090), the Fundación Caixa-Health Research
(HR21-00761 project IL7R_LungCan), and the Comunidad de Madrid
(P2022/BMD-7225 NEXT_GEN_CART_MAD-CM). Work in the DS laboratory was funded by the CNIC; the European Union’s Horizon 2020 research
and innovation program under grant agreement ERC-2016-Consolidator
Grant 725091; MCIN/AEI/10.13039/501100011033 (PID2019-108157RB);
Comunidad de Madrid (B2017/BMD-3733 Immunothercan-CM); Atresmedia (Constantes y Vitales prize); Fondo Solidario Juntos (Banco
Santander); and “La Caixa” Foundation (LCF/PR/HR20/00075). The
CNIC was supported by the ISCIII, the MCIN and the Pro CNIC
Foundation and is a Severo Ochoa Center of Excellence (CEX2020-
001041-S funded by MCIN/AEI/10.13039/501100011033). Research in
RD laboratory was supported by the ISCIII (PI2100989) and CIBERINFEC; the European Commission Horizon 2020 Framework Programme (grant numbers 731868 project VIRUSCAN FETPROACT-2016,
and 101046084 project EPIC-CROWN-2); and the Fundación CaixaHealth Research (grant number HR18-00469 project StopEbola). Research in CNB-CSIC laboratory was funded by Fondo Supera COVID19 (Crue Universidades-Banco Santander) grant, CIBERINFEC, and
Spanish Research Council (CSIC) grant 202120E079 (to J.G.-A.), CSIC
grant 2020E84 (to M.E.), MCIN/AEI/10.13039/501100011033 (PID2020-
114481RB-I00 to J.G-A. and M.E.), and by the European CommissionNextGenerationEU, through CSIC’s Global Health Platform (PTI Salud
Global) to J.G.-A. and M.E. Work in the CIB-CSIC laboratory was supported by MCIN/AEI/10.13039/501100011033 (PID2019-104544GB-I00
and 2023AEP105 to CA, and PID2020-113225GB-I00 to F.J.B.). Cryo-EM
data were collected at the Maryland Center for Advanced Molecular Analyses which was supported by MPOWER (The University of Maryland Strategic Partnership). I.H.-M. receives the support of a fellowship from la Caixa
Foundation (ID 100010434, fellowship code: LCF/BQ/IN17/11620074)
and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no.
71367. L.R.-P. was supported by a predoctoral fellowship from the Immunology Chair, Universidad Francisco de Vitoria/Merck.S
